10-Q · May 5, 2026
Cogent Biosciences experienced a significant increase in net losses in Q1 2026, amounting to $97.4 million compared to $71.99 million in Q1 2025. The company's cash position remains strong at $866.4 million, projected…
Earnings analysis · 10-Q
COGT earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
The extracted 10-Q section contains no income statement, balance sheet, cash flow, segment, or quantitative guidance data, so period-over-period operating trends cannot be assessed. Disclosure controls were deemed…
Read full summary
The extracted 10-Q section contains no income statement, balance sheet, cash flow, segment, or quantitative guidance data, so period-over-period operating trends cannot be assessed. Disclosure controls were deemed effective as of June 30, 2026, and no material changes to internal controls were reported. The filing states that risk factors and market risks were unchanged from the 2025 Form 10-K, while disclosing new director and executive Rule 10b5-1 trading plans.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure controls effective
Management concluded that disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2026.
-
Internal controls unchanged
No change during the three months ended June 30, 2026 materially affected, or was reasonably likely to materially affect, internal control over financial reporting.
-
Director trading plan disclosed
Director Arlene Morris adopted a Rule 10b5-1 plan on May 28, 2026 to sell up to 45,510 shares through July 31, 2027, subject to pricing and other conditions.
-
Second director trading plan
Director Karen Ferrante adopted a Rule 10b5-1 plan on June 25, 2026 to sell up to 63,399 shares through June 25, 2027, subject to pricing and other conditions.
-
CEO equity plan disclosed
CEO Andrew Robbins' July 30, 2026 plan covers sales of up to 201,061 shares and exercise of 57,661 incentive stock options, with the plan expiring no later than June 30, 2027.
-
CFO equity plan disclosed
CFO John Green's July 30, 2026 plan covers sales of up to 157,337 shares and exercise of 62,619 incentive stock options, with the plan expiring no later than June 30, 2027.
What to watch
-
No updated risk-factor disclosure
The company stated there were no material changes to the risk factors in its 2025 Form 10-K filed February 17, 2026; therefore, this filing does not identify a newly elevated risk factor.
-
Multiple executive selling plans
Executive Rule 10b5-1 plans disclosed on July 30, 2026 permit sales of up to 201,061 shares by the CEO, 157,337 shares by the CFO, 27,000 shares by the CMO and 116,700 shares by the CLO, subject to pricing and other conditions.
-
Litigation and market-risk exposure
The company stated there were no material changes to market risks described in its 2025 Form 10-K filed February 17, 2026; however, the filing also notes that litigation and claims could adversely affect the company through defense and settlement costs and management-resource diversion.
Management's outlook
The extracted 10-Q text provides no quantitative revenue or EPS outlook. No change in outlook can be assessed from this filing.
Earlier filings 4
10-K · February 17, 2026
Cogent is a clinical‑stage biotech focused on bezuclastinib (KIT D816V / exon 17) with positive 2025 registrational readouts across NonAdvSM, AdvSM and GIST and NDAs submitted/being submitted; the company expects a U.S.…
10-Q · May 6, 2025
Cogent reported a quarterly net loss of $71,986 (three months ended March 31, 2025) vs $58,348 in the year-ago quarter, driven by higher R&D and G&A spend. Cash and short-term investments total $245,661 ($126,003 cash…
10-K · February 25, 2025
Cogent’s 10-K emphasizes clinical progress for lead asset bezuclastinib with completed enrollment in registration-directed trials (SUMMIT Part 2 enrolled 179 patients in Q4 2024; APEX Part 2 completed enrollment with 58…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.